Viatris Inc. (VTRS)
| Market Cap | 21.23B +76.6% |
| Revenue (ttm) | 14.74B +4.4% |
| Net Income | -410.70M |
| EPS | -0.35 |
| Shares Out | 1.15B |
| PE Ratio | n/a |
| Forward PE | 7.24 |
| Dividend | $0.48 (2.60%) |
| Ex-Dividend Date | Aug 21, 2026 |
| Volume | 5,435,601 |
| Open | 18.45 |
| Previous Close | 18.45 |
| Day's Range | 18.35 - 18.66 |
| 52-Week Range | 9.92 - 18.75 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 19.70 (+6.6%) |
| Earnings Date | Nov 5, 2026 |
About VTRS
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]
Financial Performance
In 2025, Viatris's revenue was $14.30 billion, a decrease of -2.98% compared to the previous year's $14.74 billion. Losses were -$3.51 billion, 454.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for VTRS stock is "Buy." The 12-month stock price target is $19.7, which is an increase of 6.60% from the latest price.
News
Viatris price target raised to $20 from $18 at JPMorgan
JPMorgan raised the firm’s price target on Viatris (VTRS) to $20 from $18 and keeps a Neutral rating on the shares as part of a Q3 earnings preview. Published first…
Viatris announces FDA approval of ryzumvi for treatment of presbyopia in adults
Viatris (VTRS) announced that the U.S. FDA has approved ryzumvi for the treatment of presbyopia in adults. Ryzumvi is currently approved in the United States for the treatment of pharmacologically-ind...
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences, ...
Viatris to Buy Pacira BioSciences for $1.65 Billion
Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.
Viatris: Pacira deal expected to be immediately accretive to financial guidance
“The proposed transaction is expected to be immediately accretive to our financial guidance metrics,” said Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller, Viatris (VTRS). ...
Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B
07:45 EDT Viatris (VTRS) to acquire Pacira (PCRX) for $36.50 per share in cash, or $1.65B
Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B
Viatris (VTRS) and Pacira BioSciences (PCRX) announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock…
Viatris to buy pain therapy maker Pacira Biosciences for $1.65 billion
Viatris said on Thursday it will buy Pacira Biosciences for $1.65 billion, adding the pain therapy maker's products to its portfolio.
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructur...
Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
PITTSBURGH, Oct. 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report third-quarter 2026 financial results on Thursday, November 5, 2026. Co...
Viatris price target raised to $26 from $23 at UBS
UBS raised the firm’s price target on Viatris (VTRS) to $26 from $23 and keeps a Buy rating on the shares. Viatris has outperformed year-to-date but retains further upside into…
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
PITTSBURGH, Sept. 29, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it was named to Forbes' World's Best Employers list for the sixth consecutive year.
Viatris initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Viatris (VTRS) with an Outperform rating and $25 price target The market continues to value Viatris as a declining generics and established-brands company, overlookin...
Viatris announces approval for Wakix in Japan
Viatris (VTRS) announced that Japan’s Ministry of Health, Labour and Welfare has granted approval for Wakix for the treatment of excessive daytime sleepiness, or EDS, associated with obstructive sleep...
Viatris price target raised to $13 from $12 at Piper Sandler
Piper Sandler raised the firm’s price target on Viatris (VTRS) to $13 from $12 and keeps a Neutral rating on the shares. Viatris has emerged on the broader investor radar…
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in Japan PITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare compa...
Leerink sees growth for Viatris, starts at Outperform
As previously reported, Leerink analyst Daniel Clark initiated coverage of Viatris (VTRS) with an Outperform rating and $20 price target The firm expects revenue and EBITDA growth in 2026 after…
Viatris initiated with an Outperform at Leerink
Leerink initiated coverage of Viatris (VTRS) with an Outperform rating and $20 price target
Viatris price target raised to $20 from $15 at Argus
Argus raised the firm’s price target on Viatris (VTRS) to $20 from $15 and keeps a Buy rating on the shares. The company’s favorable growth strategy is supported by a…
Harrow to acquire global rights to Tyrvaya from Viatris for up to $100M
Harrow (HROW) announced that it has entered into a definitive agreement to acquire Tyrvaya nasal spray 0.03 mg from Viatris (VTRS). Tyrvaya is a cholinergic agonist indicated for the treatment…
Viatris Earnings Call Transcript: Q2 2026
Q2 revenues grew 3.5% year-over-year to $3.8 billion, with strong performance in Greater China and North America driving a guidance raise for all key 2026 metrics. Pipeline progress, cost savings, and capital returns support long-term growth, despite supply and policy headwinds.
Viatris Slides: Q2 2026
Viatris has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Viatris Earnings release: Q2 2026
Viatris released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Viatris Quarterly report: Q2 2026
Viatris has published its Q2 2026 quarterly earnings report on August 6, 2026.